Combinostics, founded in 2014 and headquartered in Finland, is at the intersection of Enterprise Software, Health Care, Information Technology, and Robotics. The company is driven by its mission stated in its slogan: "Using a combination of science and AI technology, we aim to improve the lives of patients with neurological disorders." This sums up their focus on enhancing clinical decision-making with their flagship platform, cNeuro™. The technology leverages AI to integrate various data types—imaging biomarkers, demographic and clinical attributes, and neuropsychology test results—into actionable insights for clinicians.
Their latest funding round, a €3.90M Series A investment secured on 21 November 2019, involved notable support from Industrifonden and NordicNinja VC. This financial backing underscores investor confidence in Combinostics' potential for growth and impact within the neurological diagnostics landscape.